Press releases 2025

• ASCO 2025 : for the first time in 20 years, a new treatment shows benefit in high-risk head and neck cancers
  Press release, 1 june 2025
• ASCO 2025 : a new drug tested as a first-line treatment for poor-prognosis Ewing sarcomas
  Press release, 31 may 2025
• ASCO 2025 : a combination therapy shows signs of efficacy in treatment-resistant patients with a subtype of colorectal cancer
  Press release, 30 may 2025
• The presence of tumour DNA in the blood could shape follow-up care for cancer patients
  Press release, 19 may 2025
• Age-related genetic changes in the blood associated with poor cancer prognosis
  Press release, 25 april 2025
• Gustave Roussy is exporting its model of excellence internationally with a first branded oncology center in Egypt
  Press release, 8 april 2025
• Launch of the European programme DOSELIA: artificial intelligence in the service of paediatric radiotherapy
  Press release, 1 april 2025
• Sofinnova Partners and Gustave Roussy launch first biotech company through Strategic Partnership
  Press release, 18 march 2025
• OASIS, a new European research programme to optimise antibody-drug conjugates
  Press release, 6 february 2025
• The inaugural edition of the Gustave Roussy Prize awarded to Professor Charles Swanton
  Press release, 4 february 2025
• Resilience and the Department of Therapeutic Innovation and Early Stage Trials are leveraging remote patient monitoring for clinical research in oncology
  Press, release, 3 february 2025
• Dana-Farber and Gustave Roussy announce 2025 Transatlantic Exchange scientific program to focus on Radioligand Therapy
  Press release, 13 january 2025